MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Return on equity 2016–2024
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-126.0%FY2024 · since FY2016: -125.1% → -126.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -126.0% | -63.4 pp |
| FY2023 | -62.6% | -22.6 pp |
| FY2022 | -40.0% | -3.5 pp |
| FY2021 | -36.5% | +31.4 pp |
| FY2020 | -67.9% | +39.7 pp |
| FY2019 | -107.6% | +24.2 pp |
| FY2018 | -131.8% | +84.8 pp |
| FY2017 | -216.6% | -91.5 pp |
| FY2016 | -125.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net incomeMTNB Net marginMTNB Gross profitMTNB Gross marginMTNB Operating incomeMTNB Operating marginMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Total liabilitiesMTNB Shareholders’ equityMTNB overview →